ArticleStem cell reports2021
Low Immunogenicity and Immunosuppressive Properties of Human ESC- and iPSC-Derived Retinas.
Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Photoreceptor replacement: a disease-agnostic approach for the treatment of advanced retinal degeneration.Eye (London, England) · 2026Review
- Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Early hypoxia treatment and oxygen-concentration alteration promote the retinal progenitor proliferation and ganglion cell maturation in human retinal organoid development.Stem cell research & therapy · 2026Article
- Cell-based regenerative therapy for retinal diseases: challenges and emerging bioengineering strategies.Regenerative therapy · 2025Review
- Applications of Modern Cell Therapies: The Latest Data in Ophthalmology.Life (Basel, Switzerland) · 2025Review
- Gene and Stem Cell-Based Therapies for Retinal Degenerative Diseases: Update, Challenges, and Future Directions.Stem cell reviews and reports · 2025Review
- Impact of Donor and Host Age on Systemic Cell Therapy to Treat Age-Related Macular Degeneration.Cells · 2025Article
- Genome-edited retinal organoids restore host bipolar connectivity in the primate macula.bioRxiv : the preprint server for biology · 2025Article
- Metabolic stress and early cell death in photoreceptor precursor cells following retinal transplantation.Stem cell research & therapy · 2025Article
- Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies.Cell reports. Medicine · 2025Article
- Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025Review
- Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells.Communications medicine · 2024Article
- Towards Stem/Progenitor Cell-Based Therapies for Retinal Degeneration.Stem cell reviews and reports · 2024Review
- The application of retinal organoids in ophthalmic regenerative medicine: A mini-review.Regenerative therapy · 2024Review
- The potential of induced pluripotent stem cell-derived retinal organoids in regenerative medicine.Regenerative medicine · 2024Article
- Recent Progress in Photoreceptor Cell-Based Therapy for Degenerative Retinal Disease.Stem cells translational medicine · 2024Review
- Advancements in Human Embryonic Stem Cell Research: Clinical Applications and Ethical Issues.Tissue engineering and regenerative medicine · 2024Review
- Co-transplantation of autologous TNature · 2023Article
- Immune Responses to Sequential Binocular Transplantation of Allogeneic Retinal Progenitor Cells to the Vitreous Cavity in Mice.International journal of molecular sciences · 2023Article
- Pluripotent stem cell-derived retinal organoid/cells for retinal regeneration therapies: A review.Regenerative therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ESC- and iPSC-derived retinal transplantation is a promising therapeutic approach for disease with end-stage retinal degeneration, such as retinitis pigmentosa and age-related macular degeneration. We previously showed medium- to long-term survival, maturation, and light response of transplanted human ESC- and iPSC-retina in mouse, rat, and monkey models of end-stage retinal degeneration. Because the use of patient hiPSC-derived retina with a disease-causing gene mutation is not appropriate for therapeutic use, allogeneic transplantation using retinal tissue/cells differentiated from a stocked hESC and iPSC line would be most practical. Here, we characterize the immunological properties of hESC- and iPSC-retina and present their three major advantages: (1) hESC- and iPSC-retina expressed low levels of human leukocyte antigen (HLA) class I and little HLA class II in vitro, (2) hESC- and iPSC-retina greatly suppressed immune activation of lymphocytes in co-culture, and (3) hESC- and iPSC-retina suppressed activated immune cells partially via transforming growth factor β signaling. These results support the use of allogeneic hESC- and iPSC-retina in future clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.